EGFR-mutation-positive NSCLC cells co-express RTKs and non-RTKs, especially, Src, YES and FAK, which cannot be inhibited by single EGFR inhibitors, including the third-generation EGFR TKI osimertinib 8-10, 21-23. This evidence concerns the gene YES1 and non-small cell lung carcinoma.